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Background: We aimed to assess the current state of PKU screening and management in the region of
southeastern Europe.
Methods: A survey was performed involving all identified professionals responsible for the PKU management in
the 11 countries from South-Eastern region of Europe (Albania, Bulgaria, Bosnia and Herzegovina, Croatia, Kosovo,
Macedonia, Moldova, Montenegro, Romania, Serbia, Slovenia). The questionnaire was designed to assess the characteristics
regarding PKU management in three main areas: nation-wide characteristics, PKU screening, and characteristics of the PKU
management in the responding centre. It consisted of 56 questions. The distribution and collection of the questionnaires
(via e-mail) was taking place from December 2013 to March 2014.
Results: Responses from participants from 11 countries were included; the countries cumulative population is approx. 52.5
mio. PKU screening was not yet introduced in 4 of 11 countries. Reported PKU incidences ranged from 1/7325 to 1/39338
(and were not known for 5 countries). National PKU guidelines existed in 5 of 11 countries and 7 of 11 countries had PKU
registry (registries included 40 to 194 patients). The number of PKU centers in each country varied from 1 to 6. Routine
genetic diagnostics was reported in 4 of 11 countries. Most commonly used laboratory method to assess phenylalanine
levels was fluorometric. Tetrahydrobiopterine was used in only 2 of 11 countries. Most frequently, pediatricians were caring
for the patients. Dietitian was a member of PKU team in only 4 of 11 countries, while regular psychological assessments
were performed in 6 of 11 countries. Patient’s PKU society existed in 7 of 11 countries.
Conclusions: The region of southeastern Europe was facing certain important challenges of PKU screening and
management. Neonatal PKU screening should be introduced throughout the region. Furthermore, PKU management was
falling behind internationally established standards-of-care in many aspects.
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Phenylketonuria (PKU; MIM 261600), an autosomal
recessive disease, is the most common inborn error of
amino acid metabolism in Caucasians, where 1 in 10,000
individuals is affected, but the incidences vary substan-
tially among different populations [1, 2]. PKU is caused
by the deficiency of hepatic phenylalanine hydroxylase
(PAH; EC 1.14.16.1), which catalyzes the hydroxylation
of phenylalanine (Phe) to tyrosine (Tyr). The PAH defi-
ciency results in an accumulation of Phe, acting neuro-
toxically [1, 3] The dietary therapy based on a restricted
Phe intake prevents the neurological damage in most
cases if started soon enough after birth and if guided
with frequent monitoring of Phe concentrations [4]. Fifty
years ago, Guthrie’s landmark discovery enabled success-
ful implementation of first newborn screening programs
for PKU, which have been implemented throughout the
developed world [5].
All current guidelines, recommendations and reviews
on PKU screening and management agree on some basic
facts and requirements. Most notably that PKU screening
is a prerequisite for an early implementation of the Phe-
restricted diet, which is necessary to prevent the severe
neurological impairment, observed in untreated PKU pa-
tients [6, 7]. Furthermore, dietary PKU treatment with
regular monitoring of blood Phe levels is mandatory at
least throughout childhood, adolescence, and in pregnant
women, but ideally throughout the life etc. [8]. Very re-
cently, the European Society for Phenylketonuria and
Allied Disorders (E.S.PKU) proposed a need for recom-
mendations for a minimum standard of care for PKU,
guaranteeing equal access to screening, treatment and
monitoring throughout Europe [9]. Nevertheless, PKU
screening and management practices vary widely through-
out the individual PKU centers, countries and regions,
and large parts of the world might fall behind even the
basic standards. Relatively few previous international stud-
ies on PKU management have been performed, mostly fo-
cusing on the more developed parts of Europe, while large
parts of eastern and southeastern Europe could not be
assessed in previous European surveys [10–15].
Since very scarce data exist on PKU management in
region of southeastern Europe, the aim of our study
was to assess the current state of PKU screening and
management in the region of southeastern Europe
(i.e. Balkan Peninsula countries).
Methods
Study design and questionnaire
Survey was performed involving all identified profes-
sionals responsible for the PKU management in the
countries from South-Eastern region of Europe (Albania,
Bulgaria, Bosnia and Herzegovina, Croatia, Kosovo,
Macedonia, Moldova, Montenegro, Romania, Serbia,Slovenia). From one to five participants from each par-
ticipating country were included in survey, as suggested
by the responsible person from each country. The ques-
tionnaire was designed to assess the characteristics
regarding PKU management in three main areas: nation-
wide characteristics, PKU screening, and characteristics
of the PKU management in the responding centre. It
consisted of altogether 56 questions (13 of them were on
general aspects of neonatal screening, which were ana-
lyzed separately). The full questionnaire is provided as
an online Additional file 1.
The first part of the questionnaire included the ques-
tions on PKU screening characteristics (year of introduc-
tion; number and proportion of newborn screened; age
when screened; PKU/HPA incidences; laboratory screen-
ing method; Phe cut-off ). The second part included
questions on nation-wide characteristics of PKU man-
agement (PKU guidelines; number and type of PKU cen-
ters; PKU registry; definition of metabolic phenotypes;
on who cares for PKU patients; availability of medical
food, low protein food and tetrahydrobiopterine (BH4),
money reimbursements/money support; existence of
patient’s society, membership in E.S.PKU). The third
part included questions on specific characteristics of
responding PKU center (number of patients to follow-up
according to age, diet, metabolic phenotypes; number of
lost to follow-up, genetic analyses; laboratory methods
used; BH4 use; composition of PKU team, dietary plans
preparation; psychological assessments; care for adults;
care for pregnant women).
The distribution and collection of the questionnaires
was made by e-mail and was taking place from December
2013 to March 2014.
Data analysis
All responses were compiled in a spreadsheet, and most
of the open questions grouped or categorized and tabu-
lated. Descriptive analyses were performed in the form
of sums (reported as percent of total responses) and me-
dians. From each country (with exception of Bosnia and
Herzegovina where three different responses for Sarajevo
Canton, for Republic of Srpska and for Federation of
Bosnia and Herzegovina without Sarajevo were obtained,
reflecting the functioning of their healthcare system as
three effectively separate subsystems, including the new-
born screening) only single completed questionnaires
were obtained, filled and e-mailed by the responsive par-
ticipant from each country, who in some instances com-
pleted the questionnaire with help by other professionals
from the country, which were also listed as coauthors.
Answers to some of the questions could not be included
as the variations between responses were too large or
too few responses were received and thus no meaningful
grouping and interpretation of results could be made.
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current status of PKU management in the region of
South-Eastern Europe, especially to elucidate the com-
mon difficulties in PKU management in the region.Results
Responses from participants from all 11 countries were
included; the countries cumulative population was
approx. 52.5 mio; Montenegro had the smallest popula-
tion (0.63 mio.) and Romania the largest (18.91 mio.).
Bosnia and Herzegovina was effectively divided in 3 sep-
arately functioning healthcare systems, including the
newborn screening systems, despite a small population
of 3.8 mio. The GDP per capita ranged from around


































0.44 9392 2006 5152/5167 Un










Kosovo 1.74 8436 NI -/34,262 Un
Macedonia 2.06 11,834 NI -/23752 Un
Moldova 3.50 4219 1989 36,654/
39,641
1/7
Montenegro 0.63 14,358 NI -/8156 Un






7.18 11,801 1983 52,094/
49,325f
1/3
Slovenia 2.05 28,476 1979 21,888/
21,938
1/1
BL only in region Banja Luka; cap capita; CS cesarean section; est. estimation; FBH Fe
geneticists; h hours; Int internists; nbs newborns; Nd no data available; NI not introd
preparation; Rep. Republic; Tz only in Tuzla Canton; Zg only in city Zagreb
aNumber includes some newborns from Brcko District
bKremensky et al, please see ref. [17]
cBulgarian national PKU registry was established in the year 2000; Romanian nation
patients diagnosed afterwards
dKaracic et al, please see ref. [23]
eHyperphenylalaninemias cumulatively; Published in: Boiciuc K, Usurelu N, Stratila M
neonatal si analiza molecular genetic. In Patologa malformativa neonatal. Edited by
Technopress; 2013:146–153
fNumber of screened newborns includes some screening cards from Vojvodina and
gStojiljkovic et al, please see ref. [18]
hGroselj et al, please see ref. [22]of newborns in 2012 ranged from 8156 (Montenegro) to
195,000 (Romania) (Table 1).
PKU newborn screening was not introduced in 4 of 11
countries (Albania, Kosovo, Macedonia, Montenegro). In
two countries (Bulgaria, Romania) where the newborn
screening was introduced, over 10 % of newborns were
not screened. Number of newborn screening centers
ranged from none to five (Romania). Most commonly
used screening method was fluorometric, while Guthrie’s
test was still used in Croatia and enzymatic/colorimetric
method in Serbia. The Phe cut-off values ranged from 2
to 4 mg/dl. Reported estimates of PKU incidences
ranged from 1/7325 to 1/39,338 (and were not known
for 5 countries). Six of 11 countries had established na-
tional PKU registries and one country had registry in
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Stamatin M, Stratulat P. Zilele Neonatologiei Moldave,
Montenegro
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the children and adult patients (Bosnia, Croatia, Serbia,
Slovenia), internists were following the adult patients in
Bulgaria, Macedonia and Romania but geneticists were
responsible for all PKU patients in Moldova (Table 1).
The number of PKU centers in each country varied
from one to six. Bulgaria and Romania had one adult
only PKU center each, while all the other countries had
combined pediatric/adult or pediatric only PKU centers.
The responding PKU centers were following up to 176
PKU patients on dietary treatment. Only three centers
were also following patients with BH4 deficiency. Rou-
tine genetic diagnostics was reported by PKU centers in
four of 11 countries. Most commonly used laboratory
method to monitor Phe levels was fluorometric. In
Kosovo, Macedonia and Albania Phe-free amino acids
supplements and low protein food were not reimbursed.
The patients got no financial support for low protein
food in Bulgaria and Moldova. BH4 was routinely used
in only 2 of 11 countries. Dietitian was a member of
PKU team in only 4 of 11 countries. Psychological as-
sessments were regularly performed in 6 of 11 countries
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ePlanned in near future and will be financed by the health insuranceinvolvement of a neuropsychologist. The management
of maternal PKU was reported in 5 countries (Table 2).
National PKU guidelines existed in five of 11 countries
(Bulgaria, Croatia, Moldova, Serbia, Slovenia) based on
several different published recommendations. Some
countries are following U.K. and U.S.A. guidelines
(Bosnia, Bulgaria, Macedonia) or USSR recommenda-
tions (Moldova). Seven of 11 countries had patients/par-
ents PKU society, while only in six of 11 countries
reported to be E.S.PKU members.
Discussion
This was the first study to assess the PKU screening and
management characteristics in the region of southeast-
ern Europe, involving 11 countries from the region with
a cumulative population of approx. 52.5 mio. The in-
cluded populations are thought to be ethnically and gen-
etically very heterogeneous, which was reflected also by
the variations of PKU incidences [15–17]. Even within
the same country large differences are reported; for in-
stance, in Croatia, the incidence of PKU in the region
“Hrvatsko Zagorje” is about 1/3.500, while in the region
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cantly lower incidences in Serbia and Bulgaria [17, 18].
The reported PAH genotypes from the participating coun-
tries in different genetic studies are reflecting the hetero-
geneity of the populations but numerous historically
documented migrations over the Balkan Peninsula were
causing genetic similarity to other Caucasian populations
[18–24]. The incidences are not known for 4 countries
without newborn screening, while only estimations were
possible for Bosnia and Romania. Taking the birth rates in
the 4 countries without screening and the PKU incidence
of 1/10,000 the expected number of the PKU patients
would be 10 per year. The number seems low but the
many lost screening years in this region in the last 40 years
are suggesting a much higher number of missed oppor-
tunities for the diagnosis and treatment of PKU.
The most disturbing fact shown by our survey was that
the PKU newborn screening was not introduced in 4 of 11
countries (Albania, Kosovo, Macedonia, Montenegro),
while in two other countries (Bulgaria, Romania) where it
was introduced, over 10 % of newborns were not screened.
Thus large parts of the region were falling behind the
internationally established standards regarding the PKU
screening [6, 8]. In the countries with non existing new-
born screening none or very few patients with PKU were
diagnosed. In the countries with implemented newborn
screening, the total numbers of diagnosed PKU patients
born before the implementation of the newborn screening
were available, but were very low as compared to the ex-
pected number of PKU patients based on the PKU
incidences.
The possibility of treatment was very limited in
Kosovo, Albania and Macedonia because amino acids
supplements and low protein food were not reimbursed,
while patients in Bulgaria and Moldova were reported
not to get any additional financial support for the low
protein diet. The nutritional recommendations and tar-
get Phe values in blood could be hardly met without suf-
ficient amounts of low-Phe protein substitutes and low
protein food. The unavailability and high prices of the
medical food would be a further important limitation for
PKU treatment in these countries in case of successful
consolidation of newborn screening throughout the
region.
Almost half of the countries reported the use of the
national PKU guidelines. Fundamentally they are based
on several published recommendations and the manage-
ment of the patients is very similar [13, 25]. Surprisingly
a dietitian was a part of PKU team in only 4 countries
and in other PKU centers the dietary plan was a respon-
sibility of the physicians. Previous European surveys
show that basic PKU team consists of a physician and a
dietitian [11–13], which was not shown to be a regular
practice in the region of southeastern Europe. Thequality of the dietary PKU management without a spe-
cialized dietitian may be insufficient. The multidisciplin-
ary approach to include a dietitian is consistent with the
requirements for minimum standards of care for PKU
[9], which any European country should be encouraged
to adopt.
The economic backgrounds of the participating coun-
tries were also very heterogeneous, four of 11 countries
had GDP per capita under 10,000 USD and nine of 11
countries under 20,000 USD. Moldova with lowest GDP
per capita maintained better standards of PKU screening
and management as compared to some other countries
with relatively 2 to 3-times higher GDP per capita. Fi-
nancial situation seemed not to be the most important
factor of the standard of the PKU screening and
management, which we believe was an important and
encouraging finding of the study.
The newly published proceedings of the PKU scientific
review conference are providing one of the most compre-
hensive and up-to-date understandings of PKU available
[8]. The preparation and publication of the proceedings
perfectly coincides with fifty years anniversary of the
Guthrie’s discovery and implementation of first newborn
screening programs for PKU. In the 1970s the screening
for PKU was mandatory in nearly all industrialized
European countries [26]. PKU screening is a prerequisite
for an early implementation of the phenylalanine-
restricted diet, preventing and eliminating the severe
neurological impairment typical for untreated PKU pa-
tients [5, 27]. Nevertheless, the people from many devel-
oping countries throughout the world are not taking a
part in any of advances in the field of PKU of the last
50 years [28]. The report from year 2004 that outlined the
status of neonatal screening for PKU has included 7 coun-
tries from southeastern Europe [29]. Moldova had no
screening in year 2004 and Montenegro was a part of
Serbian screening program [18, 29]. The breakup of
former Yugoslavia after inter-ethnic wars resulted in newly
established countries with limited resources. Conse-
quently, the screening statistics is not significantly better
after 10 years. Bosnia, Bulgaria, Croatia, Serbia and
Slovenia continued or improved the screening program
while other countries in the region with the exception of
Romania did not implement the screening [30].
Sporadic reports from certain developing countries
(e.g. Tunisia, Lebanon, Iran) without newborn PKU
screening show PKU to be one of the most common
preventable causes of mental retardation [28, 31–33]. A
significant group of mentally impaired patients is ex-
pected in Balkan Peninsula because of the late or absent
introduction of the screening [30, 34]. Additionally the
families miss the opportunity for genetic counseling
without a proper diagnosis and maternal PKU is not pre-
vented. Furthermore, some other studies are showing
Zerjav Tansek et al. Orphanet Journal of Rare Diseases  (2015) 10:68 Page 6 of 7that the introduction of newborn screening in develop-
ing countries would clearly be a cost-effective decision
[28, 35].
We firmly believe that implementation of basic stan-
dards of PKU management to the developing parts of
the world should be among priorities when identifying
future medical and research needs, while these efforts
should be supported by relevant professional forums,
patients’ organizations and also industry [9, 28]. One
such emerging initiative is that by the E.S.PKU, which
very recently proposed the need for recommendations
for a minimum standard of care for PKU, also arguing
for equal access to screening, treatment and monitoring
throughout Europe [9].
Conclusions
This was the first study to assess the PKU screening and
management characteristics in the 11 countries from
southeastern Europe, identifying several important chal-
lenges. Neonatal PKU screening should be introduced
throughout the region. Furthermore, PKU management
was falling behind internationally established standards-
of-care in many aspects. We firmly believe that imple-
mentation of basic standards of PKU management to
the developing parts of the world should be among fu-
ture priorities.
Additional file
Additional file 1: Questionnaire on the PKU management and the
newborn screening in the region of the South-Eastern Europe.
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